{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Head+and+Neck+Cancer&page=2", "query": { "condition": "Advanced Head and Neck Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Head+and+Neck+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T02:12:18.760Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003182", "title": "Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hope Cancer Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "1997-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-05-22T02:12:18.760Z", "location_count": 2, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003182" }, { "nct_id": "NCT03094169", "title": "AVID100 in Advanced Epithelial Carcinomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AVID100 IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Formation Biologics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2017-02-01", "completion_date": "2021-01-30", "has_results": true, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-05-22T02:12:18.760Z", "location_count": 10, "location_summary": "New Haven, Connecticut • Grand Rapids, Michigan • New York, New York + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03094169" }, { "nct_id": "NCT03621982", "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer Squamous Cell Carcinoma", "Non-small Cell Lung Cancer", "Gastric Cancer", "Esophageal Cancer", "Pancreas Cancer", "Bladder Cancer", "Renal Cell Carcinoma", "Melanoma", "Triple-negative Breast Cancer", "Ovarian Cancer", "Colo-rectal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "ADCT-301", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ADC Therapeutics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2018-11-09", "completion_date": "2022-12-14", "has_results": true, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-05-22T02:12:18.760Z", "location_count": 5, "location_summary": "Palo Alto, California • New Haven, Connecticut • Portland, Oregon + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03621982" }, { "nct_id": "NCT04440943", "title": "A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "MSI-H Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Other Solid Tumors" ], "interventions": [ { "name": "CDX-527", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-08-04", "completion_date": "2023-04-06", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-05-22T02:12:18.760Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04440943" }, { "nct_id": "NCT07030257", "title": "Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor Malignancies", "Colorectal Carcinoma", "Small Cell Lung Cancer ( SCLC )", "Head and Neck (HNSCC)", "Bladder Cancer", "Non-Small Cell Lung Cancer", "Pancreatic Cancer, Advanced or Metastatic" ], "interventions": [ { "name": "CP-383", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tasca Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-08-27", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-02-18", "last_synced_at": "2026-05-22T02:12:18.760Z", "location_count": 13, "location_summary": "Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07030257" }, { "nct_id": "NCT00004233", "title": "S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "triacetyluridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2001-02", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2011-07-25", "last_synced_at": "2026-05-22T02:12:18.760Z", "location_count": 97, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004233" }, { "nct_id": "NCT02159703", "title": "A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oropharyngeal Cancer" ], "interventions": [ { "name": "TORS", "type": "PROCEDURE" }, { "name": "Adjuvant Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2014-02", "completion_date": "2018-02", "has_results": true, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-05-22T02:12:18.760Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02159703" }, { "nct_id": "NCT01259284", "title": "Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Fish Oil Supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2011-01", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2012-08-07", "last_synced_at": "2026-05-22T02:12:18.760Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01259284" }, { "nct_id": "NCT00923247", "title": "A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Medullary Thyroid Carcinoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Vandetanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 22, "start_date": "2009-02-19", "completion_date": "2016-12-09", "has_results": true, "last_update_posted_date": "2018-11-29", "last_synced_at": "2026-05-22T02:12:18.760Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923247" }, { "nct_id": "NCT04651634", "title": "MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Oral Mucositis" ], "interventions": [ { "name": "MIT-001 plus CCRT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MitoImmune Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-06-21", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-05-22T02:12:18.760Z", "location_count": 6, "location_summary": "Gilbert, Arizona • Los Angeles, California • Wichita, Kansas + 3 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Rochester", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04651634" } ] }